isoflurane

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

About Ask DrugCentral

Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.

General architecture

Ask a questionThe browser sends your question to the same-origin Django chat API.
Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.

Using the assistant

Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.

Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.

Property	Description	Value
kinase-safety-class	ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAP2K6,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CG,PRKDC,SIK2,STK33,SYK,TEK	31
kinase-selectivity-class	PDK1,PDK2	2
pfas-class	PFAS structural alert (1 = True, 0 = False)	1

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Mitochondrial DNA mutation	185.61	61.02	28	2681	430	90625308
Intra-abdominal pressure increased	166.26	61.02	24	2685	267	90625471
Propofol infusion syndrome	162.18	61.02	29	2680	1310	90624428
Necrosis ischaemic	136.77	61.02	24	2685	971	90624767
Pneumatosis	132.56	61.02	21	2688	450	90625288
Blood gases abnormal	131.87	61.02	23	2686	898	90624840
Gene mutation	130.50	61.02	26	2683	2104	90623634
Hyperthermia malignant	117.62	61.02	22	2687	1276	90624462
Intestinal ischaemia	117.00	61.02	31	2678	8852	90616886
CSF oligoclonal band present	111.62	61.02	18	2691	433	90625305
Multiple-drug resistance	111.35	61.02	29	2680	7747	90617991
Systemic inflammatory response syndrome	106.49	61.02	27	2682	6489	90619249
Pleocytosis	103.58	61.02	19	2690	989	90624749
Apnoea	101.23	61.02	28	2681	9386	90616352
Metabolic acidosis	85.94	61.02	39	2670	55637	90570101
Delayed recovery from anaesthesia	84.13	61.02	16	2693	1014	90624724
Blood lactic acid increased	80.25	61.02	23	2686	8755	90616983
Arrhythmia	76.07	61.02	33	2676	42299	90583439
Post procedural complication	74.05	61.02	26	2683	19016	90606722
Electrocardiogram QT prolonged	73.27	61.02	38	2671	72418	90553320
Shock	70.52	61.02	28	2681	28750	90596988
Blood creatine phosphokinase increased	69.33	61.02	29	2680	33994	90591744
Exposure during pregnancy	67.02	61.02	56	2653	238354	90387384
Status epilepticus	66.68	61.02	24	2685	18850	90606888
Partial seizures	66.26	61.02	19	2690	7241	90618497
Hypotension	64.96	61.02	63	2646	325334	90300404
Ultrasound ovary abnormal	63.38	61.02	9	2700	88	90625650
Perforation	62.52	61.02	14	2695	1980	90623758

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyperthermia malignant	299.99	56.03	60	2361	2598	42616316
Hypotension	116.26	56.03	104	2317	257527	42361387
Apnoea	109.90	56.03	33	2388	7770	42611144
Intestinal ischaemia	103.89	56.03	33	2388	9355	42609559
Necrosis ischaemic	102.65	56.03	18	2403	373	42618541
Post procedural complication	102.13	56.03	35	2386	12555	42606359
Superinfection	90.47	56.03	23	2398	2928	42615986
Fear	83.17	56.03	29	2392	10936	42607978
Systemic inflammatory response syndrome	81.84	56.03	26	2395	7364	42611550
Anhedonia	80.98	56.03	26	2395	7614	42611300
Mucosal ulceration	80.34	56.03	18	2403	1336	42617578
Injury	76.04	56.03	33	2388	22283	42596631
Renal injury	68.91	56.03	26	2395	12254	42606660
Emotional distress	62.09	56.03	26	2395	16067	42602847
Blood lactic acid increased	56.13	56.03	20	2401	8019	42610895

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyperthermia malignant	414.63	46.08	81	5026	3819	110580373
Intestinal ischaemia	235.42	46.08	67	5040	16112	110568080
Necrosis ischaemic	231.49	46.08	42	5065	1317	110582875
Systemic inflammatory response syndrome	185.17	46.08	53	5054	12990	110571202
Hypotension	181.86	46.08	167	4940	523682	110060510
Mitochondrial DNA mutation	172.29	46.08	28	5079	448	110583744
Propofol infusion syndrome	152.70	46.08	33	5074	2556	110581636
Intra-abdominal pressure increased	149.25	46.08	24	5083	358	110583834
Blood lactic acid increased	129.06	46.08	42	5065	15779	110568413
Fear	120.74	46.08	44	5063	23149	110561043
Metabolic acidosis	120.07	46.08	68	5039	99676	110484516
Renal injury	114.41	46.08	40	5067	18673	110565519
Anhedonia	113.96	46.08	38	5069	15390	110568802
Blood gases abnormal	112.92	46.08	23	5084	1335	110582857
Gene mutation	111.98	46.08	27	5080	3402	110580790
Pneumatosis	107.58	46.08	21	5086	980	110583212
Delayed recovery from anaesthesia	107.15	46.08	24	5083	2191	110582001
CSF oligoclonal band present	102.95	46.08	18	5089	454	110583738
Pleocytosis	85.14	46.08	19	5088	1705	110582487
Emotional distress	80.65	46.08	40	5067	44807	110539385
Blood creatine phosphokinase increased	80.35	46.08	47	5060	73030	110511162
Superinfection	79.88	46.08	23	5084	5740	110578452
Unevaluable event	75.61	46.08	42	5065	59185	110525007
Bradycardia	74.82	46.08	60	5047	155457	110428735
Respiratory acidosis	74.81	46.08	27	5080	13799	110570393
Mucosal ulceration	73.92	46.08	18	5089	2361	110581831
Renal failure	68.19	46.08	67	5040	226507	110357685
Anaesthetic complication	66.49	46.08	18	5089	3588	110580604
Shock	62.97	46.08	36	5071	53552	110530640
Multiple-drug resistance	61.10	46.08	23	5084	13212	110570980
Ultrasound ovary abnormal	59.46	46.08	9	5098	88	110584104
Procedural complication	59.27	46.08	20	5087	8385	110575807
Procedural hypotension	58.11	46.08	15	5092	2490	110581702
Perforation	57.80	46.08	14	5093	1796	110582396
Left ventricular hypertrophy	57.48	46.08	22	5085	13222	110570970
Hyperkalaemia	56.14	46.08	48	5059	135748	110448444
Drug interaction	54.58	46.08	89	5018	500094	110084098
Arrhythmia	54.31	46.08	36	5071	69539	110514653
Multiple organ dysfunction syndrome	53.49	46.08	49	5058	151661	110432531
Cardiac arrest	51.53	46.08	54	5053	196699	110387493
Antinuclear antibody positive	49.95	46.08	18	5089	9150	110575042
Partial seizures	49.78	46.08	19	5088	11330	110572862
Torsade de pointes	49.22	46.08	23	5084	22577	110561615
Electrocardiogram QT prolonged	48.08	46.08	40	5067	108920	110475272

Source	Code	Description
ATC	N01AB06	NERVOUS SYSTEM ANESTHETICS ANESTHETICS, GENERAL Halogenated hydrocarbons
MeSH PA	D000777	Anesthetics
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D018685	Anesthetics, Inhalation
CHEBI has role	CHEBI:22587	antiviral agent
CHEBI has role	CHEBI:35554	cardiovascular drug
CHEBI has role	CHEBI:38870	inhalation anaesthetic
FDA EPC	N0000175681	General Anesthetic
FDA PE	N0000175975	General Anesthesia

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

isoflurane 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products:

Disease	Relation	SNOMED_ID	DOID
General anesthesia	indication	50697003
Hyperkalemia	contraindication	14140009
Low blood pressure	contraindication	45007003
Duchenne muscular dystrophy	contraindication	76670001	DOID:11723
Disease of liver	contraindication	235856003	DOID:409
Malignant hyperthermia	contraindication	405501007

Species	Use	Relation
Dogs	Induction and maintenance of general anesthesia	Indication
Horses	Induction and maintenance of general anesthesia	Indication

Product	Applicant	Ingredients
IsoFlo	Zoetis Inc.	1
Isoflurane, USP	Dechra Veterinary Products LLC	1
ATTANE	Piramal Critical Care Inc.	1
Isoflurane, USP	Piramal Enterprises Ltd.	1

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
GABA-A receptor; anion channel	Ion channel	O00591 O14764 P14867 P18505 P18507 P28472 P31644 P34903 P47869 P47870 P48169 P78334 Q16445 Q8N1C3 Q99928 Q9UN88	GBRP_HUMAN GBRD_HUMAN GBRA1_HUMAN GBRB1_HUMAN GBRG2_HUMAN GBRB3_HUMAN GBRA5_HUMAN GBRA3_HUMAN GBRA2_HUMAN GBRB2_HUMAN GBRA4_HUMAN GBRE_HUMAN GBRA6_HUMAN GBRG1_HUMAN GBRG3_HUMAN GBRT_HUMAN	POSITIVE ALLOSTERIC MODULATOR			CHEMBL	CHEMBL
Potassium channel subfamily K member 2	Ion channel	O95069	KCNK2_HUMAN	OPENER			CHEMBL	CHEMBL
Potassium channel subfamily K member 3	Ion channel	O14649	KCNK3_HUMAN	OPENER			CHEMBL	CHEMBL
Potassium channel subfamily K member 9	Ion channel	Q9NPC2	KCNK9_HUMAN	OPENER			CHEMBL	CHEMBL
Potassium channel subfamily K member 10	Ion channel	P57789	KCNKA_HUMAN	OPENER			CHEMBL	CHEMBL
Potassium channel subfamily K member 18	Ion channel	Q7Z418	KCNKI_HUMAN	OPENER			CHEMBL	CHEMBL
Glycine receptor (alpha-1/beta)	Ion channel	P23415 P48167	GLRA1_HUMAN GLRB_HUMAN	POSITIVE MODULATOR			CHEMBL	CHEMBL
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	5.11	PDSP

ID	Source
4019107	VUID
N0000147364	NUI
D00545	KEGG_DRUG
4019107	VANDF
C0022180	UMLSCUI
CHEBI:6015	CHEBI
ICF	PDB_CHEM_ID
CHEMBL1256	ChEMBL_ID
DB00753	DRUGBANK_ID
D007530	MESH_DESCRIPTOR_UI
3763	PUBCHEM_CID
3286	INN_ID
2505	IUPHAR_LIGAND_ID
CYS9AKD70P	UNII
6026	RXNORM
284	MMSL
4326	MMSL
4926	MMSL
d00267	MMSL
001391	NDDF
387368002	SNOMEDCT_US
66492008	SNOMEDCT_US

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
FORANE	HUMAN PRESCRIPTION DRUG LABEL	1	10019-360	INHALANT	1 mL	RESPIRATORY (INHALATION)	NDA	26 sections
Isoflurane	HUMAN PRESCRIPTION DRUG LABEL	1	12164-012	LIQUID	1 mL	RESPIRATORY (INHALATION)	ANDA	22 sections
Isoflurane	HUMAN PRESCRIPTION DRUG LABEL	1	42677-326	LIQUID	100 mL	RESPIRATORY (INHALATION)	ANDA	16 sections
Isoflurane	HUMAN PRESCRIPTION DRUG LABEL	1	42677-327	LIQUID	250 mL	RESPIRATORY (INHALATION)	ANDA	16 sections
Terrell	HUMAN PRESCRIPTION DRUG LABEL	1	66794-011	LIQUID	1 mL	RESPIRATORY (INHALATION)	ANDA	28 sections
Isoflurane	HUMAN PRESCRIPTION DRUG LABEL	1	66794-017	LIQUID	1 mL	RESPIRATORY (INHALATION)	ANDA	28 sections
Terrell	HUMAN PRESCRIPTION DRUG LABEL	1	66794-019	LIQUID	1 mL	RESPIRATORY (INHALATION)	ANDA	31 sections
Terrell	HUMAN PRESCRIPTION DRUG LABEL	1	66794-019	LIQUID	1 mL	RESPIRATORY (INHALATION)	ANDA	31 sections
Isoflurane	HUMAN PRESCRIPTION DRUG LABEL	1	66794-020	LIQUID	1 mL	RESPIRATORY (INHALATION)	ANDA	28 sections
Isoflurane, (Volatile for Inhalation)	HUMAN PRESCRIPTION DRUG LABEL	1	83301-0071	LIQUID	100 mL	RESPIRATORY (INHALATION)	ANDA	28 sections
Isoflurane, (Volatile for Inhalation)	HUMAN PRESCRIPTION DRUG LABEL	1	83301-0072	LIQUID	250 mL	RESPIRATORY (INHALATION)	ANDA	28 sections